MCID: DRM014
MIFTS: 60

Dermatofibrosarcoma Protuberans malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Cancer diseases

Aliases & Classifications for Dermatofibrosarcoma Protuberans

About this section
Sources:
49OMIM, 10Disease Ontology, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 24GTR, 65UMLS, 36MeSH, 59SNOMED-CT, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Dermatofibrosarcoma Protuberans:

Name: Dermatofibrosarcoma Protuberans 49 10 45 22 23 47 12 51 24 65
Dermatofibrosarcoma 23 47 36 65
Dfsp 45 23 51
Metastatic Dermatofibrosarcoma Protuberans 45 65
 
Giant Cell Fibroblastoma 45 65
Familial Dermatofibrosarcoma Protuberans 45
Darier-Hoffmann Tumor 23
Darier-Ferrand Tumor 23

Characteristics:

Orphanet epidemiological data:

51
dermatofibrosarcoma protuberans:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: adult

Classifications:



External Ids:

OMIM49 607907
Disease Ontology10 DOID:3507
MeSH36 D018223
Orphanet51 31112
MESH via Orphanet37 C538219
UMLS via Orphanet66 C0392784
UMLS65 C0206647, C0392784, C3693482 C3665732, more

Summaries for Dermatofibrosarcoma Protuberans

About this section
NIH Rare Diseases:45 Dermatofibrosarcoma protuberans is an uncommon cancer in which tumors arise in the deeper layers of skin. the tumor usually starts as a small, firm patch of skin; it may be purplish, reddish, or flesh-colored. it is commonly found on the torso, usually in the shoulder and chest area. the tumor typically grows slowly but has a tendency to recur after being removed. it rarely spreads to other parts of the body. the cause of dfsp is unknown, but injury to the affected skin may be a predisposing factor. treatment usually involves surgically removing the tumor. if the tumor is unable to be removed completely, additional therapy may be needed. regular follow-up is important to monitor for recurrence. last updated: 2/9/2016

MalaCards based summary: Dermatofibrosarcoma Protuberans, also known as dermatofibrosarcoma, is related to diabetic neuropathy and renal cell carcinoma, and has symptoms including thickened skin, neoplasm of the skin and sarcoma. An important gene associated with Dermatofibrosarcoma Protuberans is PDGFB (Platelet Derived Growth Factor Subunit B), and among its related pathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Cytoskeleton remodeling_Role of PDGFs in cell migration. Affiliated tissues include the dermis laryer of the skin, skin and breast, and related mouse phenotypes are pigmentation and renal/urinary system.

Disease Ontology:10 A fibrosarcoma that is located in the dermis laryer of the skin and that begins as a hard nodule and grows slowly.

Genetics Home Reference:23 Dermatofibrosarcoma protuberans is a rare type of cancer that causes a tumor in the deep layers of skin. This condition is a type of soft tissue sarcoma, which are cancers that affect skin, fat, muscle, and similar tissues.

OMIM:49 Dermatofibrosarcoma protuberans (DFSP) is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep... (607907) more...

Wikipedia:68 Dermatofibrosarcoma protuberans (DFSP) is a very rare tumor. It is a rare neoplasm of the dermis layer... more...

Related Diseases for Dermatofibrosarcoma Protuberans

About this section

Diseases related to Dermatofibrosarcoma Protuberans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 477)
idRelated DiseaseScoreTop Affiliating Genes
1diabetic neuropathy30.3F13A1, PDGFB, TGFBR2
2renal cell carcinoma30.3KIT, PDGFB, PDGFRB, TP53
3autoimmune lymphoproliferative syndrome30.3CD34, PDGFB, PDGFRB, TP53
4glioma30.1PDGFRA, PDGFRB, TP53
5myelodysplastic syndrome29.9CD34, KIT, PDGFRB, TP53
6bednar tumor12.1
7myxofibrosarcoma11.6
8beemer ertbruggen syndrome10.6COL1A1, PDGFB
9prostatitis10.5
10endotheliitis10.5
11leukemia10.5
12adenocarcinoma10.5
13primary trimethylaminuria10.5PDGFB, PDGFRB
14prostate cancer10.4
15breast cancer10.4
16lymphoma10.4
17neuronitis10.4
18pulmonary fibrosis, familial10.4F13A1, HABP2
19spindle cell liposarcoma10.4CD34, TP53
20sarcomatosis10.4CD34, TP53
21benign deep fibrous histiocytoma10.4COL1A1, F13A1, PDGFB
22sclerosing liposarcoma10.4CD34, PDGFB
23conventional fibrosarcoma10.4CD34, COL1A1, PDGFB
24vulval paget's disease10.4CD34, TP53
25cerebellar medulloblastoma10.4NES, TP53
26colorectal cancer10.4
27systemic lupus erythematosus10.4
28arthritis10.4
29hepatitis10.4
30esophagitis10.4
31melanoma10.4
32cervicitis10.4
33retinitis10.4
34influenza10.4
35lupus erythematosus10.4
36cardiomyopathy10.4
37space motion sickness10.4NES, TP53
38anus leiomyosarcoma10.4CD34, KIT
39severe canavan disease10.4PDGFRA, PDGFRB
40submandibular gland cancer10.4CD34, KIT
41lymphangiosarcoma10.4CD163, PDGFB
42simple partial epilepsy10.3CD34, KIT
43ovary rhabdomyosarcoma10.3CD34, KIT
44indolent systemic mastocytosis10.3CD34, KIT
45conventional angiosarcoma10.3CD34, KIT
46small intestinal sarcoma10.3CD34, KIT
47cutaneous leiomyosarcoma10.3CD34, KIT
48littre gland carcinoma10.3CD163, CD34
49cutaneous solitary mastocytoma10.3CD34, KIT
50uterine corpus atypical polypoid adenomyoma10.3CD163, CD34

Graphical network of the top 20 diseases related to Dermatofibrosarcoma Protuberans:



Diseases related to dermatofibrosarcoma protuberans

Symptoms for Dermatofibrosarcoma Protuberans

About this section


Clinical features from OMIM:

607907

Symptoms:

 51
  • erythema/erythematous lesions/erythroderma/polymorphous erythema
  • thick skin/pachydermia/orange skin
  • subcutaneous nodules/lipomas/tumefaction/swelling
  • skin/cutaneous neoplasm/tumor/carcinoma/cancer (excluding melanoma)
  • soft tissue sarcoma/cancer/tumor/liposarcoma/myosarcoma
  • chronic skin infection/ulcerations/ulcers/cancrum

HPO human phenotypes related to Dermatofibrosarcoma Protuberans:

id Description Frequency HPO Source Accession
1 thickened skin hallmark (90%) HP:0001072
2 neoplasm of the skin hallmark (90%) HP:0008069
3 sarcoma hallmark (90%) HP:0100242
4 skin ulcer typical (50%) HP:0200042

Drugs & Therapeutics for Dermatofibrosarcoma Protuberans

About this section

Drugs for Dermatofibrosarcoma Protuberans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxorubicinapproved, investigationalPhase 3, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
2
MechlorethamineapprovedPhase 330951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
╬▓,╬▓'-dichlorodiethyl-N-methylamine
3
IfosfamideapprovedPhase 33713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
4
DoxilApproved June 1999Phase 3, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
5Topoisomerase InhibitorsPhase 3, Phase 14081
6Antineoplastic Agents, AlkylatingPhase 3, Phase 13406
7Anti-Bacterial AgentsPhase 3, Phase 19140
8Antibiotics, AntitubercularPhase 3, Phase 15971
9Alkylating AgentsPhase 3, Phase 13582
10Isophosphamide mustardPhase 3371
11
Sunitinibapproved, investigationalPhase 2486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
12
PaclitaxelapprovedPhase 1, Phase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
13Angiogenesis Modulating AgentsPhase 23611
14Immunosuppressive AgentsPhase 2, Phase 110422
15Angiogenesis InhibitorsPhase 23688
16Imatinib MesylatePhase 1, Phase 2577123596
17
saracatinibPhase 231
Synonyms:
AZD 0530
 
AZD0530
saracatinib
18Protein Kinase InhibitorsPhase 1, Phase 23162
19Tubulin ModulatorsPhase 1, Phase 24279
20Antineoplastic Agents, PhytogenicPhase 1, Phase 24294
21taxanePhase 1, Phase 2324
22Albumin-Bound PaclitaxelPhase 1, Phase 22621
23Antimitotic AgentsPhase 1, Phase 24296
24tyrosineNutraceuticalPhase 1, Phase 2596
25
Cyclophosphamideapproved, investigationalPhase 1264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
26Antirheumatic AgentsPhase 18496
27Immunologic FactorsPhase 118483
28Antibodies, MonoclonalPhase 12413
29AntibodiesPhase 14477
30ImmunoglobulinsPhase 14477

Interventional clinical trials:

(show all 20)
idNameStatusNCT IDPhase
1Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue SarcomaRecruitingNCT00334854Phase 3
2Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaActive, not recruitingNCT00346164Phase 3
3Imatinib in Dermatofibrosarcoma Protuberans (DFSP)CompletedNCT00122473Phase 1, Phase 2
4Neoadjuvant Imatinib in Dermatofibrosarcoma ProtuberansCompletedNCT00243191Phase 2
5Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
6Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell FibroblastomaCompletedNCT00085475Phase 2
7Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
8Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
9AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2
10Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
11Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
12To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsRecruitingNCT01962103Phase 1, Phase 2
13Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisActive, not recruitingNCT00555581Phase 2
14Phase II Pazopanib Study in Advanced DermatofibrosarcomasTerminatedNCT01059656Phase 2
15Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue SarcomaTerminatedNCT00740597Phase 2
16Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00720174Phase 1
17Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 1
18Clinical Outcome of Pediatric Dermatofibrosarcoma ProtuberansRecruitingNCT00173355
19Spanish Registry of Mohs SurgeryRecruitingNCT02310503
20Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for SarcomaWithdrawnNCT00334984

Search NIH Clinical Center for Dermatofibrosarcoma Protuberans


Cochrane evidence based reviews: dermatofibrosarcoma

Genetic Tests for Dermatofibrosarcoma Protuberans

About this section

Genetic tests related to Dermatofibrosarcoma Protuberans:

id Genetic test Affiliating Genes
1 Dermatofibrosarcoma Protuberans22 PDGFB

Anatomical Context for Dermatofibrosarcoma Protuberans

About this section

MalaCards organs/tissues related to Dermatofibrosarcoma Protuberans:

33
Skin, Breast, Lung, T cells, Prostate, Thyroid, Heart

FMA organs/tissues related to Dermatofibrosarcoma Protuberans:

16
The dermis laryer of the skin

Animal Models for Dermatofibrosarcoma Protuberans or affiliated genes

About this section

MGI Mouse Phenotypes related to Dermatofibrosarcoma Protuberans:

38 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.2COL1A1, KIT, PDGFB, PDGFRA, TP53
2MP:00053678.8COL1A1, KIT, PDGFB, PDGFRA, PDGFRB, TP53
3MP:00053898.6COL1A1, F13A1, KIT, PDGFB, PDGFRA, PDGFRB
4MP:00107718.6CD34, COL1A1, KIT, PDGFB, PDGFRA, PDGFRB
5MP:00053708.6COL1A1, HABP2, KIT, PDGFB, TGFBR2, TP53
6MP:00053818.4COL1A1, KIT, PDGFRA, PDGFRB, TGFBR2, TP53
7MP:00053808.3COL1A1, KIT, PDGFB, PDGFRA, PDGFRB, TGFBR2
8MP:00053828.3COL1A1, KIT, PDGFRA, PDGFRB, TGFBR2, TP53
9MP:00053888.3COL1A1, F13A1, KIT, PDGFB, PDGFRA, TGFBR2
10MP:00053698.1COL1A1, KIT, PDGFB, PDGFRA, PDGFRB, TGFBR2
11MP:00020068.0CD34, COL1A1, KIT, MMP11, PDGFRA, TGFBR2
12MP:00053877.1CD34, COL1A1, HABP2, KIT, PDGFB, PDGFRA
13MP:00053977.0CD34, COL1A1, F13A1, KIT, PDGFB, PDGFRA
14MP:00053856.9APOD, COL1A1, F13A1, KIT, MMP11, PDGFB
15MP:00053766.4APOD, CD34, COL1A1, F13A1, HABP2, KIT

Publications for Dermatofibrosarcoma Protuberans

About this section

Articles related to Dermatofibrosarcoma Protuberans:

(show top 50)    (show all 576)
idTitleAuthorsYear
1
miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. (25003366)
2014
2
Adherence With Postdischarge Venous Thromboembolism Chemoprophylaxis Recommendations After Colorectal Cancer Surgery Among Elderly Medicare Beneficiaries. (24169191)
2013
3
Interleukin-17F single-nucleotide polymorphism (7488T>C) and its association with susceptibility to leprosy. (24164796)
2013
4
Pancytopenia from severe cobalamin (vitamin B12) deficiency in Johanson-Blizzard syndrome. (23900243)
2013
5
Severe thymic hyperplasia in a newborn calf associated with impaired T-cell differentiation. (23864259)
2013
6
Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. (23154767)
2012
7
Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. (23136569)
2012
8
Epiretinal membrane after pars plana vitrectomy for primary pseudophakic or aphakic rhegmatogenous retinal detachment: incidence and outcomes. (22414957)
2012
9
Penile herpes zoster: an unusual location for a common disease. (22218522)
2011
10
Activator-independent transcription of Snf1-dependent genes in mutants lacking histone tails. (21338416)
2011
11
A rare case of cervical schistosomiasis in Wales. (21534771)
2011
12
Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. (21707078)
2011
13
Response to growth hormone therapy in adolescents with familial panhypopituitarism. (20431169)
2010
14
Near-fatal subdural empyema complicating a rapidly progressive orbital cellulites. (20930977)
2010
15
Casein-derived tripeptide, Val-Pro-Pro (VPP), modulates monocyte adhesion to vascular endothelium. (19907102)
2009
16
Escape of the yolk sac: a hypothesis to explain the embryogenesis of gastroschisis. (19419415)
2009
17
Safety of concomitant tamoxifen and warfarin. (19843839)
2009
18
The inhibitory co-receptors: a way to save from anergy the HIV-specific T cells. (19442121)
2009
19
Effects and underlying mechanisms of human opiorphin on colonic motility and nociception in mice. (19442408)
2009
20
Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. (19106169)
2009
21
An autopsy case of granulocyte-colony-stimulating-factor-producing extrahepatic bile duct carcinoma. (18473424)
2008
22
Pathology quiz case 2. Alveolar rhabdomyosarcoma. (18936365)
2008
23
Role of surgery in pulmonary multidrug-resistant tuberculosis. (17468453)
2007
24
Histone-deacetylases inhibitors: from TSA to SAHA]. (16455503)
2006
25
Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. (16198371)
2005
26
Adenylyl and guanylyl cyclase activity in the choroid. (15051471)
2004
27
Expression of caspase-3 and c-myc in non-small cell lung cancer. (20368820)
2004
28
Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis. (15511627)
2004
29
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. (12540499)
2003
30
Cutaneous malignant hemangiopericytoma with unusual clinical behavior. (12081167)
2002
31
Pulmonary epithelioid hemangioendothelioma coexistent with pulmonary metastasis of thyroid cancer. (11518122)
2001
32
Expression and function of CD30 on T lymphocytes. (10483869)
1999
33
T. Duckett Jones and his criteria for the diagnosis of acute rheumatic fever. (9926367)
1999
34
A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. (9435443)
1998
35
Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. (9405166)
1997
36
Stimulation of placental prorenin secretion by selective inhibition of cyclic nucleotide phosphodiesterases. (7540392)
1995
37
CGRP in the serum of endotoxin-treated rats suppresses lymphoproliferation. (7696715)
1994
38
Cysteine sulfinate decarboxylase in brain: identification, characterization and immunocytochemical location in astrocytes. (7887266)
1994
39
A novel Yes-related kinase, Yrk, is expressed at elevated levels in neural and hematopoietic tissues. (8455940)
1993
40
NMR solution structure of the [Ala26]parathyroid-hormone-related protein(1-34) expressed in humoral hypercalcemia of malignancy. (8425530)
1993
41
Mechanism of interleukin-1 beta stimulation of human amnion prostaglandin biosynthesis: mediation via a novel inducible cyclooxygenase. (8153084)
1993
42
A case of 17 alpha-hydroxylase deficiency with chromosomal karyotype 46,XY and high plasma aldosterone concentration. (1769794)
1991
43
Action of bradykinin at the cyclooxygenase step in prostanoid synthesis through the arachidonic acid cascade. (1810149)
1991
44
Tumor cells in intraoperative pleural lavage. An indicator for the poor prognosis of bronchogenic carcinoma. (2317757)
1990
45
Ventilation scintigraphy with submicronic radioaerosol as an adjunct in the diagnosis of congenital lobar emphysema. (3598706)
1987
46
Inverted papilloma of the ureter. (7253066)
1981
47
Congenital fibrosarcoma. (13095275)
1953
48
49
50

Variations for Dermatofibrosarcoma Protuberans

About this section

Expression for genes affiliated with Dermatofibrosarcoma Protuberans

About this section
Search GEO for disease gene expression data for Dermatofibrosarcoma Protuberans.

Pathways for genes affiliated with Dermatofibrosarcoma Protuberans

About this section

Pathways related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

(show all 23)
idSuper pathwaysScoreTop Affiliating Genes
19.7NES, PDGFB, PDGFRB
2
Show member pathways
9.6PDGFB, PDGFRA, PDGFRB
39.6PDGFB, PDGFRA, PDGFRB
4
Show member pathways
9.6PDGFB, PDGFRA, PDGFRB
59.6PDGFB, PDGFRA, PDGFRB
69.5NES, PDGFB, PDGFRA
79.4CD34, KIT, PDGFB
89.3COL1A1, PDGFB, PDGFRA, PDGFRB
99.2PDGFB, PDGFRA, PDGFRB, TP53
10
Show member pathways
9.2PDGFB, PDGFRA, PDGFRB, TP53
119.2CD163, CD34, KIT
129.2CD163, CD34, KIT
13
Show member pathways
9.1KIT, PDGFB, PDGFRA, PDGFRB
14
Show member pathways
9.0PDGFB, PDGFRA, PDGFRB, TGFBR2
158.9KIT, PDGFRA, PDGFRB, TP53
16
Show member pathways
8.8PDGFRA, PDGFRB, TGFBR2, TP53
178.6PDGFB, PDGFRA, PDGFRB, TGFBR2, TP53
188.6PDGFB, PDGFRA, PDGFRB, TGFBR2, TP53
19
Show member pathways
8.5COL1A1, KIT, PDGFB, PDGFRA, PDGFRB, TP53
208.5COL1A1, KIT, PDGFB, PDGFRA, PDGFRB, TP53
21
Show member pathways
8.4KIT, PDGFB, PDGFRA, PDGFRB, TGFBR2
228.4HMGA2, PDGFB, PDGFRA, PDGFRB, TP53
238.1KIT, PDGFB, PDGFRA, PDGFRB, TGFBR2, TP53

GO Terms for genes affiliated with Dermatofibrosarcoma Protuberans

About this section

Biological processes related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayGO:003579310.7PDGFB, PDGFRB
2paracrine signalingGO:003800110.6CD34, PDGFB
3positive regulation of DNA biosynthetic processGO:200057310.5PDGFB, PDGFRB
4stem cell proliferationGO:007208910.5CD34, NES
5negative regulation of platelet activationGO:001054410.3PDGFB, PDGFRA
6collagen fibril organizationGO:003019910.3COL1A1, MMP11
7retina vasculature development in camera-type eyeGO:006129810.3PDGFRA, PDGFRB
8positive regulation of chemotaxisGO:005092110.3PDGFB, PDGFRB
9positive regulation of smooth muscle cell migrationGO:001491110.3PDGFB, PDGFRB
10regulation of phosphatidylinositol 3-kinase signalingGO:001406610.1PDGFB, PDGFRA, PDGFRB
11platelet-derived growth factor receptor signaling pathwayGO:004800810.1PDGFB, PDGFRA, PDGFRB
12platelet activationGO:003016810.0COL1A1, F13A1, PDGFB
13wound healingGO:00420609.8COL1A1, PDGFB, PDGFRA, PDGFRB
14positive regulation of phospholipase C activityGO:00108639.8KIT, PDGFRA, PDGFRB
15phosphatidylinositol-mediated signalingGO:00480159.8KIT, PDGFRA, PDGFRB
16transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.7KIT, PDGFRA, PDGFRB
17positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.7KIT, PDGFRA, PDGFRB
18protein autophosphorylationGO:00467779.7KIT, PDGFRA, PDGFRB
19stem cell differentiationGO:00488639.7HMGA2, KIT
20response to estradiolGO:00323559.7COL1A1, PDGFB, PDGFRB
21positive regulation of reactive oxygen species metabolic processGO:20003799.5PDGFB, PDGFRB, TGFBR2, TP53
22fibroblast growth factor receptor signaling pathwayGO:00085439.4KIT, PDGFB, PDGFRA, PDGFRB
23positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.4KIT, PDGFB, PDGFRA, PDGFRB
24cell chemotaxisGO:00603269.3KIT, PDGFB, PDGFRA, PDGFRB
25activation of MAPKK activityGO:00001869.2KIT, PDGFB, PDGFRA, PDGFRB
26insulin receptor signaling pathwayGO:00082869.1KIT, PDGFB, PDGFRA, PDGFRB
27regulation of cell proliferationGO:00421279.1KIT, PDGFB, TGFBR2
28positive regulation of gene expressionGO:00106288.3HMGA2, KIT, PDGFB, TP53

Molecular functions related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor bindingGO:00484079.9PDGFRA, PDGFRB
2glycosaminoglycan bindingGO:00055399.9HABP2, TGFBR2
3vascular endothelial growth factor bindingGO:00380859.9PDGFRA, PDGFRB
4protein tyrosine kinase activityGO:00047139.3KIT, PDGFRA, PDGFRB

Sources for Dermatofibrosarcoma Protuberans

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet